Screening for depression in psoriasis patients during a dermatological consultation: A first step towards treatment.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
29
05
2020
accepted:
29
03
2021
pubmed:
2
9
2021
medline:
11
11
2021
entrez:
1
9
2021
Statut:
ppublish
Résumé
Depression is a highly prevalent comorbidity in psoriatic patients. The aim of this prospective study was to follow up psoriasis patients at risk for depression and to evaluate individual pathways to mental health care and the efficacy of depression screening in a real-life setting. In this prospective multicenter study, 355 patients with psoriasis were screened for depressive symptoms with the revised Beck Depression Inventory (BDI-II). General practitioners of patients at risk for depression were asked for further evaluation. One year later, information on mental health care provision was gathered. 130 patients were screened positive for depressive symptoms, and 71 patients were followed-up (follow-up rate: 54.6 %). Psychiatric treatment was recommended for 28.2 % and accepted by 23.9 % of patients. Parameters of disease activity of psoriasis (PASI: 3.1, ∆: -1.7, P = 0.018), quality of life (Dermatology Life Quality Index [DLQI]: 6.5, ∆: -2.8, P = 0.005), and depressive symptoms (BDI-II: 13.2, ∆: -8.3, P < 0.001) improved significantly. Decrease of the BDI-II score was more pronounced in patients with higher PASI decrease. Screening for depressive symptoms led to increased utilization of mental health care and improvement of psoriasis, depressive symptoms, and quality of life. Thus, such screening should be implemented in routine care to optimize patient management.
Sections du résumé
BACKGROUND AND OBJECTIVES
Depression is a highly prevalent comorbidity in psoriatic patients. The aim of this prospective study was to follow up psoriasis patients at risk for depression and to evaluate individual pathways to mental health care and the efficacy of depression screening in a real-life setting.
PATIENTS AND METHODS
In this prospective multicenter study, 355 patients with psoriasis were screened for depressive symptoms with the revised Beck Depression Inventory (BDI-II). General practitioners of patients at risk for depression were asked for further evaluation. One year later, information on mental health care provision was gathered.
RESULTS
130 patients were screened positive for depressive symptoms, and 71 patients were followed-up (follow-up rate: 54.6 %). Psychiatric treatment was recommended for 28.2 % and accepted by 23.9 % of patients. Parameters of disease activity of psoriasis (PASI: 3.1, ∆: -1.7, P = 0.018), quality of life (Dermatology Life Quality Index [DLQI]: 6.5, ∆: -2.8, P = 0.005), and depressive symptoms (BDI-II: 13.2, ∆: -8.3, P < 0.001) improved significantly. Decrease of the BDI-II score was more pronounced in patients with higher PASI decrease.
CONCLUSIONS
Screening for depressive symptoms led to increased utilization of mental health care and improvement of psoriasis, depressive symptoms, and quality of life. Thus, such screening should be implemented in routine care to optimize patient management.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1451-1461Informations de copyright
© 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386: 983-94.
De Korte J, Mombers FM, Sprangers MA et al. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002; 138: 1221-7; discussion 27.
Dowlatshahi EA, Wakkee M, Arends LR et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol 2014; 134: 1542-51.
Kurd SK, Troxel AB, Crits-Christoph P et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-5.
Patel N, Nadkarni A, Cardwell LA et al. Psoriasis, depression, and inflammatory overlap: A review. Am J Clin Dermatol 2017; 18: 613-20.
Strober B, Gooderham M, de Jong E et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol 2018; 78: 70-80.
Dommasch ED, Li T, Okereke OI et al. Risk of depression in women with psoriasis: a cohort study. Br J Dermatol 2015; 173: 975-80.
Wohlrab J, Fiedler G, Gerdes S et al. Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Arch Dermatol Res 2013; 305: 91-8.
Radtke MA, Mrowietz U, Feuerhahn J et al. Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis. J Dtsch Dermatol Ges 2015; 13: 674-90.
Lecrubier Y. Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies. J Clin Psychiatry 2007; 68(Suppl 2): 36-41.
Burton C, Simpson C, Anderson N. Diagnosis and treatment of depression following routine screening in patients with coronary heart disease or diabetes: a database cohort study. Psychol Med 2013; 43: 529-37.
Gilbody S, Sheldon T, House A. Screening and case-finding instruments for depression: a meta-analysis. CMAJ 2008; 178: 997-1003.
Jani BD, Purves D, Barry S et al. Challenges and implications of routine depression screening for depression in chronic disease and multimorbidity: a cross sectional study. PLoS One 2013; 8: e74610.
Kronish IM, Moise N, Cheung YK et al. Effect of depression screening after acute coronary syndromes on quality of life: The CODIACS-QoL randomized clinical trial. JAMA Intern Med 2019; 180(1): 45-53.
Pouwer F, Tack CJ, Geelhoed-Duijvestijn PH et al. Limited effect of screening for depression with written feedback in outpatients with diabetes mellitus: a randomised controlled trial. Diabetologia 2011; 54: 741-8.
Yawn BP, Dietrich AJ, Wollan P et al. TRIPPD: a practice-based network effectiveness study of postpartum depression screening and management. Ann Fam Med 2012; 10: 320-9.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-4.
Beck AT, Steer RA, Brown GK. Beck Depression Inventory 2nd edn. The Psychological Corporation, San Antonio, 1996.
Harter M, Klesse C, Bermejo I et al. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch Arztebl Int 2010; 107: 700-8.
Gerdes S, Wilsmann-Theis D, Celis D et al. Two questions may be enough - screening for depression in patients with psoriasis: a multicenter study. J Dtsch Dermatol Ges 2020; 18(10): 1115-25.
Nast A, Amelunxen L, Augustin M et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. J Dtsch Dermatol Ges 2018; 16: 645-69.
Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord 2012; 142 (Suppl): S8-21.
Connerney I, Shapiro PA, McLaughlin JS et al. Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study. Lancet 2001; 358: 1766-71.
Wittchen HU, Jacobi F. Die Versorgungssituation psychischer Störungen in Deutschland. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2001; 44: 993-1000.
Reich K, Armstrong AW, Langley RG et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019; 394: 831-9.
Koo J, Marangell LB, Nakamura M et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol 2017; 31: 1999-2009.
Min C, Kim M, Oh DJ et al. Bidirectional association between psoriasis and depression: Two longitudinal follow-up studies using a national sample cohort. J Affect Disord 2020; 262: 126-32.
Vallerand IA, Lewinson RT, Parsons LM et al. Depression as a risk factor for the development of psoriasis: a retrospective cohort study in the United Kingdom. Br J Dermatol 2020; 183(4): 776-8.
Zusman EZ, Howren AM, Park JYE et al. Epidemiology of depression and anxiety in patients with psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum 2020; 50(6): 1481-8.
Bush K, Kivlahan DR, McDonell MB et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998; 158: 1789-95.